Efficacy and Safety of Tralokinumab in Adolescents With Moderate to Severe Atopic Dermatitis: The Phase 3 ECZTRA 6 Randomized Clinical Trial

IMPORTANCE: Safe and effective long-term treatments for adolescents with moderate to severe atopic dermatitis (AD) are limited. OBJECTIVE: To evaluate the efficacy and safety of interleukin-13–targeted treatment with tralokinumab monotherapy in adolescents with AD. DESIGN, SETTING, AND PARTICIPANTS:...

Descripción completa

Detalles Bibliográficos
Autores principales: Paller, Amy S., Flohr, Carsten, Cork, Michael, Bewley, Anthony, Blauvelt, Andrew, Hong, H. Chih-ho, Imafuku, Shinichi, Schuttelaar, Marie L. A., Simpson, Eric L., Soong, Weily, Arlert, Petra, Lophaven, Katja Wendicke, Kurbasic, Azra, Soldbro, Lise, Vest, Natacha Strange, Wollenberg, Andreas
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Medical Association 2023
Materias:
Original Investigation
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10116386/
https://www.ncbi.nlm.nih.gov/pubmed/37074705
http://dx.doi.org/10.1001/jamadermatol.2023.0627

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10116386/
https://www.ncbi.nlm.nih.gov/pubmed/37074705
http://dx.doi.org/10.1001/jamadermatol.2023.0627

Ejemplares similares